返回
Starpharma Holdings Ltd（SPHRY）价格
SPHRY 股价走势图
SPHRY 财务
Starpharma Holdings Ltd
$2.3
-11.53%
$-0.3
收盘价：Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
盘后：Jan 16, 20:00:00 GMT-5
关键数据
前收盘价
$2.6
开盘价
$2.3
当日区间
$2.3 - $2.3
52周范围
$0.47 - $2.86
交易量
1.1K
平均成交量
1.0K
每股收益（TTM）
-0.16
股息收益率
--
市值
$96.1M
什么是 SPHRY？
Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The firm's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The firm's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. The company also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The firm has applied its DEP technology to the innovative area of antibody-drug conjugates.